Mene Pangalos via YouTube

As­traZeneca says its block­buster Farx­i­ga proved to be a game-chang­er in CKD — wrap­ping PhI­II ear­ly

If the FDA can still hold up its end of the bar­gain, As­traZeneca is al­ready on a short path to scoop­ing up a cut­ting-edge win with a like­ly ap­proval for their SGLT2 drug Farx­i­ga in cut­ting the risk of heart fail­ure. Now the phar­ma gi­ant says it can point to sol­id ev­i­dence that the drug — ini­tial­ly re­strict­ed to di­a­betes — al­so works for chron­ic kid­ney dis­ease, po­ten­tial­ly adding a block­buster in­di­ca­tion for the fran­chise.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters